Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

Germany Nephrology Biomarkers - A Market Snapshot

VIEWS: 9 PAGES: 7

Germany Nephrology Biomarkers - A Market Snapshot Summary GlobalData’s report, “Germany Nephrology Biomarkers - A Market Snapshot” provides key information and analysis on the nephrology biomarkers market in Germany. The report provides information on the applications of different biomarkers in the diagnosis of renal failure and monitoring of patients post transplant. The report analyses the market size and volume of key biomarkers such as Serum Creatinine (SCr) and Neutrophil Gelatinase Associated Lipocalin (NGAL) in Germany. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. Scope - Applications of Biomarkers in the Diagnosis of Kidney Conditions such as Acute Renal Failure and Chronic Kidney Disease. - Analysis and Comparison of Various Nephrology Biomarkers currently used by physicians. - Market Sizing and Volumes of Key Nephrology Biomarkers in Germany for the year 2010. - Key Information on Major Players with Neutrophil Gelatinase Associated Lipocalin (NGAL)-based immunoassays. - Insights on Possible Trends in the Nephrology Biomarker market due to the demand for early detection of renal failure. Reasons to buy - Develop business strategies by understanding the opportunities and unmet needs in the German Nephrology Biomarker market. - Understand and invest in key enhancements to technology to meet potential client needs in diagnosis of renal failures. - Design and develop your marketing and sales strategies - Develop market expansion strategies. - Exploit M&A opportunities by identifying key areas of growth.

More Info
  • pg 1
									                 Germany Nephrology Biomarkers - A Market Snapshot
      Reference Code: GDME0755VPT                                                                                                             Publication Date: June 2011


      1      Table of Contents                                                                         2     Summary
      1 Table of Contents.................................................................1            Nephrology biomarkers play a vital role in the diagnosis and
       1.1 List of Tables .................................................................1           monitoring of kidney function. Acute Kidney Injury (AKI) affects
       1.2 List of Figures ................................................................1
                                                                                                       about 13 million globally every year, causing about 4 million
      2 Summary .............................................................................1
      3 Germany Nephrology Biomarkers – A Market Snapshot .....1                                       deaths annually. Chronic Kidney Disease (CKD), on the other
       3.1 Nephrology Biomarkers, Applications ............................1                           hand, is the most prevalent form of kidney disease, increasing
         3.1.1    Diagnostic Tests for Renal Failure .......................2                          at an annual rate of about 6-8%. Renal failure, besides causing
         3.1.2    Use of Biomarkers in Post Transplant Therapeutic                                     a significant number of fatalities also contributes to substantial
                  Drug Monitoring (TDM) Practices .........................3                           healthcare expenses. Around 8-10% of the European
       3.2 Nephrology Biomarkers, Comparison by Type ..............3                                   population suffers from some form of Chronic Renal Failure
         3.2.1    Other Types of Biomarkers Used .........................3
                                                                                                       (CRF). The number of patients undergoing treatment for CRF in
       3.3 Germany Nephrology Biomarkers: Market
            Characterization ............................................................4             the form of dialysis has doubled over the last 15 years. If the
         3.3.1    Nephrology Biomarkers (SCr) Market, Germany,                                         same trend continues, this would put a great burden on
                  Revenue ($m) and Volume (‘000), by Site, 2010 .4                                     healthcare systems, and would increase healthcare budget
         3.3.2    Nephrology Biomarkers (NGAL) Market,                                                 expenditure on CRF treatment by 3-5%. In addition, renal
                  Germany, Revenue ($’000) and Volume (‘000), by                                       dysfunction diseases are also related to severe co-morbid
                  Site, 2010 .............................................................4
                                                                                                       conditions such as cardiovascular disease or diabetes, thereby
         3.3.3    Nephrology Biomarkers (NGAL) Market,
                  Germany, Key Players and Products, 2010 .........5                                   increasing the risk of mortality. Accurate and early diagnosis of
      4 Appendix ..............................................................................5       renal disorders is necessary to tackle the healthcare problems
       4.1 Research Methodology .................................................6                     associated with kidney disease. Biomarkers such as Serum
       4.2 Secondary Research .....................................................6                   Creatinine (SCr) and cystatin C play an important role in
       4.3 Primary Research..........................................................6                 detecting renal conditions. The need for early detection of renal
       4.4 Models ...........................................................................6         dysfunction has also driven the emergence of new early
       4.5 Forecasts.......................................................................7
                                                                                                       biomarkers such as Neutrophil Gelatinase Associated Lipocalin
       4.6 Expert Panels ................................................................7
       4.7 GlobalData Consulting ..................................................7                   (NGAL).
       4.8 Contact Us.....................................................................7            The German nephrology biomarkers market is valued at
       4.9 Disclaimer......................................................................7
                                                                                                       approximately $9m in 2010, of which more than 95% of the
                                                                                                       market is contributed by SCr tests. The German market for
      1.1       List of Tables
                                                                                                       these nephrology biomarkers has been estimated based on the
      Table 1:       List of Other Potential Biomarkers Used in                                        usage of biomarkers in different care settings. While SCr is a
                     Nephrology, 2010 .....................................................3
                                                                                                       major contributor for both inpatient and outpatient clinical tests
      Table 2:       Nephrology Biomarkers (SCr) Market, Germany,
                     Market Size ($m), Volume (‘000), by Care Setting,                                 used for detection of renal conditions, NGAL is a promising new
                     2010 .........................................................................4   marker used only in inpatient settings.
      Table 3:       Nephrology Biomarkers (NGAL) Market, Germany,
                     Revenue ($’000), Volume (‘000), by Care-Setting,                                  3     Germany Nephrology Biomarkers – A
                     2010 .........................................................................5         Market Snapshot
      Table 4:       Nephrology Biomarkers (NGAL) Market, Germany,
                     Key Players and Products, 2010 ..............................5                    3.1    Nephrology Biomarkers, Applications
      1.2       List of Figures                                                                        Renal failure or renal dysfunction is a serious fatal condition
                                                                                                       associated with the partial or complete failure in the functioning
      Figure 1: Nephrology Biomarkers, Comparison, by Type ........3
                                                                                                       of the kidneys. It is characterized by inhibited excretory and
      Figure 2: Nephrology Biomarkers (SCr) Market, Germany,
                Revenue ($m), Volume (‘000), by Care Setting, 2010                                     fluid regulatory functions. Kidneys are vital organs that perform
                .................................................................................4     several important functions, such as removing waste and water
      Figure 3: Nephrology Biomarkers (NGAL) Market, Germany,                                          from blood, controlling blood pressure, helping to produce Red
                Revenue ($’000), Volume (‘000), by Care-Setting,                                       Blood Cells (RBCs), keeping bones strong by producing an
                2010 .........................................................................4        active form of Vitamin D, as well as balancing body chemicals




                                                                                                                                                         Market Analysis Alerts
                                                                                                                                    GDME0755VPT / Published JUN 2011 / Page 1
Germany Nephrology Biomarkers - A Mar
								
To top